Bosentan in Treatment of Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that
constitutes a great burden at the individual as well as the familial and social level. The
combination of critically increased pulmonary vascular resistance, progressive pressure load
of the right ventricle and disturbance of pulmonary gas exchange result in long-term
polymorbidity. The objective of this study is to look into the effects of medium-term
pulmonary pressure-lowering treatment with oral bosentan in patients with congenital heart
defects and clinically relevant pulmonary arterial hypertension (PAH), taking advantage of
extensive diagnostic procedures.
Phase:
Phase 4
Details
Lead Sponsor:
Competence Network for Congenital Heart Defects
Collaborators:
Actelion German Federal Ministry of Education and Research